Medigene CFO Leaves
This article was originally published in Scrip
Medigene AG's CFO Peter Llewellyn-Davies will be leaving the company after three years – effective March 31, 2016. During his time at Medigene, Llewellyn-Davies contributed to the repositioning of the company towards cancer immunotherapy. He also secured financing for the new corporate strategy through various fund raisings with participation of international investors.
Register for our free email digests: